Healthcare Affordability Access
Expert articles and analysis related to healthcare affordability access.
AI Summary — Last 7 Days
Medicare Advantage affordability and access pressures intensified this week as KFF documented 2026 plan dynamics around premiums, out-of-pocket limits, supplemental benefits, and prior authorization, while HHS OIG found the three largest MA organizations denied long-term acute care and inpatient rehabilitation requests at some of the highest rates—raising operational risk for hospitals, post-acute providers, and VBC networks dependent on timely transitions of care. At the same time, Medicaid coverage stability is becoming a near-term population health risk, with many enrollees unaware of upcoming work-reporting requirements, while KFF’s analysis of MA rebates shows continued distortion between MA-PD and stand-alone Part D markets that could affect beneficiary plan selection and medication affordability. Together, these developments point to a sharper 2026 access-management environment: VBC stakeholders will need stronger prior authorization escalation, post-acute contracting/data-sharing, and coverage-retention strategies to protect total cost of care and quality performance (KFF on MA in 2026; Healthcare Dive on Medicaid work requirements).
Related Articles
STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.
Medicare’s $35 Insulin Cap Lowered Beneficiary Costs, Increased Use for Some
The monthly spending limit improved adherence among insulin users who previously had especially high costs, Schaeffer researchers found. The post Medicare’s $35 Insulin Cap Lowered Beneficiary Costs, ...
PCMA unveils new policy platform aimed at drug affordability
PCMA unveils new policy platform aimed at drug affordability Fierce Healthcare
Why don’t health plans voluntarily cover GLP-1s for obesity?
ICER found GLP-1 drugs to be cost effective for treating obesity. If that is the case, why don’t more US payers cover the GLP-1 drugs? Clearly, one reason is the cost given the sheer volume of patient...
BCBS of Massachusetts partners for lower cost drug alternatives
BCBS of Massachusetts partners for lower cost drug alternatives Healthcare Finance News
Employers are rethinking pharmacy benefits: 5 things to know
Employers are rethinking pharmacy benefits: 5 things to know Modern Healthcare
TrumpRx Adds 160 More Drugs: Why the Latest Expansion Matters
TrumpRx Adds 160 More Drugs: Why the Latest Expansion Matters Pharmaceutical Commerce
Mental health ghost networks are badly hurting patients
Mental health ghost networks are badly hurting patients KevinMD.com
OOP Insulin Cap Stabilizes Costs, Improves Adherence
Lawmakers at the end of session try to appease both sides in drug pricing controversy
Lawmakers at the end of session try to appease both sides in drug pricing controversy Capitol News Illinois